Email updates

Keep up to date with the latest news and content from JTM and BioMed Central.

This article is part of the supplement: 7th European Workshop on Immune-Mediated Inflammatory Diseases

Open Access Poster presentation

IL-1 receptor antagonist restores IL-18 NK cell axis in systemic JIA

Sebastiaan J Vastert*, Wilco De Jager, Bo Jan Noordman, Berent J Prakken and Nico M Wulffraat

  • * Corresponding author: Sebastiaan J Vastert

Author Affiliations

Dept. of Pediatric Immunology, University Medical Center Utrecht, Utrecht, the Netherlands

For all author emails, please log on.

Journal of Translational Medicine 2012, 10(Suppl 3):P45  doi:10.1186/1479-5876-10-S3-P45

The electronic version of this article is the complete one and can be found online at:

Published:28 November 2012

© 2012 Vastert et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Systemic onset juvenile idiopathic arthritis (SoJIA) is an acquired auto-inflammatory disease characterized by systemic inflammation and innate immune activation reflected by uncontrolled production of cytokines such as IL-1, IL- 6 and IL-18. In SoJIA, NK cell function is severely hampered despite high levels of IL-18.

We recently found that defective phosphorylation of the IL-18 receptor beta is responsible for the deficient IL-18-NK cell axis in SoJIA.


To study first line treatment with recombinant IL-1 receptor antagonist (rIL-1RA, Anakinra) in 16 newly diagnosed and steroid naïve systemic onset JIA patients.

Materials and methods

Clinical outcome was measured using ACRp70 and ACRp90. Furthermore, NK cell lytic function, inflammasome activity and cytokine levels in plasma were assessed during follow up (max 3 years).


Here we show that patients with SoJIA have increased inflammasome activation leading to elevated IL-18 levels. First line treatment in steroid naïve patients, with rIL-1RA effectively down-regulated IL-18 levels through suppression of inflammasome activation and led to rapid resolution of clinical features in 87% (ACRp90) of patients. Furthermore, using rIL-1RA as first line treatment approach the defective IL-18-NK cell axis is restored as shown by improved lytic NK cell function and regaining of the NK cell responsiveness to IL-18 stimulation.


These data suggest that the mechanisms of inflammatory control induced by rIL-1RA in SoJIA patients involves more than blocking IL-1R. Our data show that rIL-1RA directly targets the inflammasome and restores the IL-18 NK cell axis as well.